Clinical Trials
48 trialsNCT01816971 2026-04-21
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
University of Chicago
Phase 2 Completed
NCT02203643 2026-04-14
FORTE
University of Turin, Italy
Phase 2 Completed
NCT02405364 2026-04-08
IFM-CRd
University Hospital, Toulouse
Phase 2 Completed
NCT02302495 2026-04-07
IFM2012-03
University Hospital, Lille
Phase 2 Completed
NCT01813227 2026-04-03
A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531
Hackensack Meridian Health
Phase 2 Completed
NCT02969837 2026-01-16
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
University of Chicago
Phase 2 Completed
NCT01665794 2025-12-22
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
University of Chicago
Phase 1/2 Completed
NCT02937571 2025-11-20
High Dose Carfilzomib for Newly Diagnosed Myeloma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02199665 2025-11-03
SINE
University of Chicago
Phase 1 Completed
NCT02512926 2025-10-15
POE14-01
Stanford University
Phase 1 Completed
NCT03773107 2025-01-13
LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma
Wake Forest University Health Sciences
Phase 1/2 Completed
NCT02148913 2024-07-26
Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma
Corewell Health West
Phase 1 Completed
NCT02073097 2024-05-29
Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT02341014 2024-04-04
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02891811 2024-03-29
Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT02318784 2023-12-05
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
SCRI Development Innovations, LLC
Phase 2 Completed
NCT03224507 2023-11-24
MASTER
University of Alabama at Birmingham
Phase 2 Completed
NCT03605719 2023-10-06
Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma
Emory University
Phase 1 Completed
NCT01301807 2023-09-29
Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01336920 2023-09-15
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
University of Nebraska
Phase 1 Completed
NCT03141203 2022-05-18
RomiCar
University of Birmingham
Phase 1/2 Completed
NCT04163107 2022-03-18
MYELOMA-HCQ
Norwegian University of Science and Technology
Phase 1 Completed
NCT02293109 2022-03-10
Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma
University of California, Davis
Phase 1 Completed
NCT01496118 2022-02-02
Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT02145403 2022-01-03
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT02187133 2021-04-23
Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
University of California, San Francisco
Phase 1 Completed
NCT02545907 2021-04-15
CATALYST
University College, London
Phase 1/2 Completed
NCT02095834 2021-01-11
Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02217163 2020-10-20
Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma
Singapore General Hospital
Phase 2 Completed
NCT01842308 2020-09-01
Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT01775930 2020-03-04
Carfilzomib in Refractory Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01372540 2019-07-16
Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01246063 2019-04-08
Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Washington University School of Medicine
Phase 1/2 Completed
NCT01549431 2019-01-16
Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma
Emory University
Phase 1 Completed
NCT02047253 2018-12-19
Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment
University of Alabama at Birmingham
Phase 2 Completed
NCT01470196 2018-11-20
CaRD
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01690143 2018-08-07
Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation
University of Alabama at Birmingham
Phase 1/2 Completed
NCT02142530 2018-01-25
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL
Massachusetts General Hospital
Phase 1 Completed
NCT01057225 2017-12-12
Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT01926665 2017-09-19
Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01775553 2017-06-21
Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT01351623 2017-04-13
Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02257476 2017-02-07
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors
Emory University
Phase 1 Completed
NCT01029054 2017-01-30
Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT01137747 2016-06-14
AML ALL
Washington University School of Medicine
Phase 1 Completed
NCT01212380 2016-05-09
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01279694 2016-04-13
CARMYSAP
Nantes University Hospital
Phase 1/2 Completed
NCT01276717 2015-12-03
Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma
University of Rochester
Phase 1 Completed